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Abstract
Background: Ring chromosome 22 is a rare human constitutional cytogenetic abnormality.
Clinical features of neurofibromatosis type 1 and 2 as well as different tumour types have been
reported in patients with ring chromosome 22. The pathogenesis of these tumours is not always
clear yet.
Methods: We report on a female patient with a ring chromosome 22 presenting with severe
mental retardation, autistic behaviour, café-au-lait macules and facial dysmorphism. Peripheral
blood lymphocytes were karyotyped and array CGH was performed on extracted DNA. At the
age of 20 years she was diagnosed with a unilateral vestibular schwannoma. Tumour cells were
analyzed by karyotyping, array CGH and NF2 mutation analysis.
Results: Karyotype on peripheral blood lymphocytes revealed a ring chromosome 22 in all
analyzed cells. A 1 Mb array CGH experiment on peripheral blood DNA showed a deletion of 5
terminal clones on the long arm of chromosome 22. Genetic analysis of vestibular schwannoma
tissue revealed loss of the ring chromosome 22 and a somatic second hit in the NF2 gene on the
remaining chromosome 22.
Conclusion: We conclude that tumours can arise by the combination of loss of the ring
chromosome and a pathogenic NF2 mutation on the remaining chromosome 22 in patients with
ring chromosome 22. Our findings indicate that patients with a ring 22 should be monitored for
NF2-related tumours starting in adolescence.
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Ring chromosome 22 [r(22)] is a rare human constitu-
tional abnormality. A distinct characteristic phenotype
has not been delineated, but frequently reported features
are delayed motor development, severe speech disability,
hypotonia and microcephaly. In addition growth retarda-
tion, ataxia and seizures or abnormal EEG can be
observed. Dysmorphic features are variable and mostly
mild. Epicanthal folds, full eyebrows and large ears have
been reported most frequently [1-4]. Aggressive behaviour
as well as autistic disorder and hyperactivity are relatively
common [1,3,4]. Internal organ involvement is rather
rare,[3] except for central nervous system malformations
[2]. The variable clinical presentation in carriers of a r(22)
has been attributed to variable breakpoints and dynamic
mosaicism. In common with other ring chromosomes,
r(22) is assumed to arise from breakage and subsequent
fusion of both chromosome arms with concomitant loss
of sequences distal to the breakpoints [5]. Whereas dele-
tion of ribosomal sequences on 22p is unlikely to be of
clinical significance, loss of critical genes on 22q as well as
unmasking of recessive alleles by the deletion may be
expected to contribute to the phenotype. In a large review
of 35 reported cases 22q loss varied from less than 69 kb
up to 10.2 Mb in size with a weak correlation between the
phenotypic variables and deletion size [3]. The phenotype
can further be affected by the continuously evolving
mosaicism (dynamic mosaicism) that is caused by the
mitotic instability of the ring chromosome. Sister chroma-
tid exchanges during mitosis can lead to formation of
dicentric or interlocked rings and subsequent aneuploidy
or rearrangements within the chromosome [6].
Clinical features compatible with neurofibromatosis type
1 (NF1) and 2 (NF2) have been associated with r(22) [7-
12]. Reported features included hearing loss, mental retar-
dation, seizures, meningiomas, peripheral neurofibro-
mas, peripheral schwannomas, spinal tumours and
vestibular schwannomas. In most reported cases the
tumoural phenotype is most suggestive of NF2. We report
on a patient with a r(22) and signs of neurofibromatosis
who presented with a unilateral vestibular schwannoma
at the age of 20. In DNA extracted from peripheral blood
lymphocytes the 22q deletion size was examined by array
CGH analysis. Analysis of tumour tissue showed loss of
the ring 22 and in addition a pathogenic NF2 mutation.
Methods
Cytogenetic studies
Cytogenetic analysis of G-banded metaphase chromo-
somes was performed according to standard cytogenetic
procedures on peripheral blood lymphocytes, skin-biopsy
derived fibroblasts and on a primary culture of Schwann
cells from the vestibular schwannoma. Culture conditions
for Schwann cells were as described by Rosenbaum et al.
[13] and Serra et al. [14].
Fluorescent In Situ Hybridisation (FISH) studies were per-
formed on skin-biopsy derived fibroblasts using probes
for NF1 (cFF13 and cFB5D) [15].
Genomic DNA was extracted from lymphocytes and ves-
tibular schwannoma using standard techniques. Array
CGH at 1 Mb resolution was carried out as described pre-
viously [16]. In the first array CGH experiment genomic
DNA of the proband was used versus female reference
DNA, in the second experiment DNA from the vestibular
schwannoma of the proband was used versus genomic
blood DNA of the proband.
Mutation analysis
NF1 mutation analysis was conducted as described previ-
ously [15]. Briefly cDNA was generated from mRNA and
used to amplify the NF1 coding region from position 48
to 8464 in eight overlapping PCR reactions. Each PCR
fragment was sequenced using a solid-phase sequencing
protocol.
To identify mutations in the NF2 gene Meta-PCR amplifi-
cation followed by direct sequence analysis of the whole
coding sequence including the immediate splice donor
and splice acceptor sites was performed. In addition the
P044 NF2 multiplex ligation-dependent probe amplifica-
tion (MLPA) kit (MRC Holland) which measures copy
number of all 17 exons of the NF2 gene and promoter was
used to identify deletions and duplications of the gene.
Loss of heterozygosity (LOH) analysis was carried out
using microsattelite markers NF2CA3 (located within
intron 1 of the NF2 gene) and D22S268 (located 5 kB tel-
omeric to NF2).
Consent
Written informed consent was obtained from the patients
parents for publication of this case report and any accom-
panying images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
Results
Case report
The proband, a female, was born by caesarian section at
the gestational age of 33 weeks. Pregnancy was compli-
cated by preeclampsia. Her birth weight was 1730 g,
length 42 cm and head circumference 30 cm. She could sit
at the age of 1.5 years and walk at 2 years. She presented a
lack of social contact. Until the age of 1.5 years she never
smiled at people and refused eye contact. She was referred
at the age of 2 years because of delayed psychomotor
development, hypotonia and autistic features. Clinical
examination showed multiple café-au-lait macules spread
over the whole body and the diagnosis of NF1 was sus-
pected (Figure 1a-b). At that time length and head circum-
ference were at the 3rd centile. During the following years
she developed freckling in the axillary and inguinalPage 2 of 7
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on the occipital region, the left hand and in the flank (Fig-
ure 1c-e). She was severely mentally retarded with lack of
speech and toilet training and had difficult, autistiform
behaviour with aggressive outbursts and automutilation.
Dysmorphic features included a small forehead and low-
set ears, large and broad hands and feet with short termi-
nal phalanges. During teenage years her length was
between the 3rd and 25th centile and head circumference
between the 25th and 50th centile. She had hyperlordosis
and bilateral pedes plani. Brain MRI at the age of 2 years
showed a lipoma of the corpus callosum. Additionally at
the age of 11 years a small T2 hyper-intense spot in the
right globus pallidus as well as a mild enlargement of the
pre-chiasmatic right optic nerve were present (Figure 2a-
b). Evaluation of vision was difficult because of the men-
tal retardation. At the age of 20 she presented with
unsteady gait, right-sided paresis of the abducens nerve
and bilateral papiloedema. Brain MRI showed a large
tumour in the right cerebello-pontine angle with com-
pression of the brainstem and cerebellum and obstructive
hydrocephalus, suggestive of vestibular schwannoma
(Figure 2c-d). The tumour was surgically removed and
pathological examination confirmed the diagnosis of a
vestibular schwannoma (Figure 3).
Cytogenetic studies
The constitutional karyotype of the patient was 46, XX, -
22, + r(22) as revealed by cytogenetic analysis of periph-
eral blood lymphocytes and of skin-biopsy derived
fibroblasts (Figure 4a). G-banded metaphases of primary
Schwann cells from the vestibular schwannoma showed
loss of the r(22) in all cells (n = 20) examined (karyotype:
45, XX, -22). FISH experiments on skin-biopsy derived
fibroblasts with probes for NF1 (cFF13 and cFB5D) were
normal.
Array CGH
Peripheral blood lymphocyte DNA
Five clones (CTA-299D3, RP5-925J7, CTA-722E9, CTA-
799F10, CTB-99K24) were deleted in the telomeric region
of chromosome 22q: del 22(q13.32 → qter), comprising
a region of approximately 2,5 Mb in size (47,248,304-
49,453,810; Ensembl database, Release 52) (Figure 4b-e).
This region also comprises the SHANK3/PROSAP2 gene,
which has been proposed as a candidate gene for the
abnormal brain development and autistic features in
patients with r(22) or 22q deletion syndrome [17,18].
vestibular schwannoma
Array CGH on DNA extracted from the vestibular schwan-
noma as the test sample and from peripheral blood of the
Phenotypic features of patient with r(22)Figure 1
Phenotypic features of patient with r(22). (a) Café-au-lait macules on the legs (b) Café-au-lait macule in the flank (c) 
Cutaneous nodule on the left hand (d) Axillary freckling (e) Inguinal freckling.Page 3 of 7
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some 22 except for the last 5 clones on 22q, confirming
the loss of the ring chromosome (Figure 5).
Mutation analysis
Sequencing of the NF1 gene did not show any pathogenic
mutations. NF2 mutation analysis was performed on
DNA from both peripheral blood and the vestibular
schwannoma. There were no NF2 sequence abnormali-
ties, intragenic deletions or copy number variations in
blood. In the tumour DNA an NF2 point mutation was
identified in a highly conserved nucleotide within the
intron 14 splice donor site (c.1122+2T>A). MLPA and
LOH analysis with two NF2 linked microsatellite markers
(D22S268 and NF2CA3) showed loss of one copy of the
NF2 gene in the vestibular schwannoma. This reflects the
loss of the r(22) in the tumour tissue as seen by karyotyp-
ing and array CGH.
Discussion
This is the first report describing the complete pathogenic
sequence of tumour formation in a patient with r(22)
with loss of the ring chromosome in the tumour tissue
and a second hit in the NF2 gene on the remaining chro-
mosome 22.
The karyotype and array CGH showed that the ring chro-
mosome 22 was lost in the vestibular schwannoma. In
addition NF2 mutation analysis on the tumour tissue
showed a somatic splice-site mutation on the remaining
chromosome 22. Predisposition for vestibular schwanno-
mas in carriers of r(22) can be explained by Knudson's
two-hit model. Due to the mitotic instability the ring
chromosome is prone to loss during somatic mitosis (first
hit). A mutation at the NF2 gene on the remaining chro-
mosome 22 (second hit) in cells that have become mono-
somic for this chromosome can result in tumour
development. This mechanism was also suspected by Tsil-
chorozidou in a patient with r(22) presenting with multi-
ple meningiomas and a unilateral vestibular
schwannoma. They found two truncating mutations in
meningioma tissue as well as loss of one copy of the NF2
gene by LOH analysis [12]. However they did not prove
loss of the ring chromosome in the tumour tissue. Inter-
estingly increased tumour development has also been
observed in carriers of other constitutional ring chromo-
somes, i.e. r(11) and r(13). Moreover the types of malig-
nancy reported in these patients are concordant with the
chromosomal assignment of tumour suppressor loci asso-
MRI images of the brain at the age of 20 yearsFigure 2
MRI images of the brain at the age of 20 years. (a) 
Horizontal T2 weighted section showing mild enlargement of 
the right optic nerve (white arrow) (b) Horizontal T2-
weighted image showing a small hyper-intense spot in the 
right globus pallidus (arrow). Note also hydrocephalus. (c-d) 
Horizontal and coronal T1 weighted images showing the 
large partly cystic contrast enhancing schwannoma in the 
right cerebello-pontine angle. The tumoural mass causes 
deviation of the brain stem and the cerebellum to the left. 
(arrow) Note also supratentorial hydrocephalus and an inter-
hemispheric lipoma (arrowhead).
Low power view of schwannomaFigure 3
Low power view of schwannoma. Low power view of 
Schwannoma, illustrating the nuclear palisading (thin arrow) 
and the hyaline vessel walls (thick arrow). H&E stain, ×300.Page 4 of 7
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blastoma (chromosome 13).
INI1 is a tumour suppressor gene located on chromosome
22 centromeric to NF2. It is involved in the development
of malignant rhabdoid tumours and germline INI1 muta-
tions are present in some cases of familial schwannoma-
tosis, a condition characterized by the development of
multiple spinal, peripheral and cranial-nerve schwanno-
mas in the absence of vestibular schwannomas [19]. It is
possible that still other tumour suppressor genes are
located on chromosome 22 [20]. Moreover the CHEK2
gene, which encodes a checkpoint kinase important for
the cell's response to DNA damage, has been recognized
as a multi-organ cancer susceptibility gene and is located
on chromosome 22 about 1 Mb centromeric to NF2. Thus
a second hit in these alternative tumour suppressor genes
in r(22) carriers that already have lost the ring in a number
of cells can result in other tumour types than those typi-
cally seen in NF2. Indeed there have been reports of r(22)
carriers with development of multiple meningiomas,
cutaneous tumours and one testicular tumour but without
the typical bilateral vestibular schwannomas of NF2
[8,11,12].
Karyotype and array CGH on peripheral blood lymphocyte DNAFigure 4
Karyotype and array CGH on peripheral blood lymphocyte DNA. (a) Detail of the constitutional karyotype of the 
patient showing the normal chromosome 22 and the ring chromosome 22. (b) Array CGH profile using a genome-wide micro-
array with a 1 Mb resolution on genomic blood DNA of the proband and female reference DNA as the control sample, show-
ing five consecutive clones with decreased copy number (encircled in blue). The Y-axis marks the hybridization ratio plotted on 
a log2 scale. Light blue dots indicate known polymorphic clones. The green and red lines indicate, respectively, the 4 × standard 
deviation [SD] threshold and the 0.58 - 2 × SD threshold [28]. (c) Detailed profile of chromosome 22 with deletion of five 
clones on the telomeric region of chromosome 22 (encircled in blue). (d) Overview of chromosome 22. The red empty square 
indicates the region shown in e. (e) Ensembl view for chromosome 22 (from 46 to 49 Mb) showing chromosome bands, 
Ensembl genes and 1 Mb clones. Deleted clones are indicated.Page 5 of 7
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a clinical diagnosis of NF1 because of multiple café-au-lait
macules, freckling, a mildly enlarged right optic nerve and
several subcutaneous nodules resembling neurofibromas.
However these clinical features do not point to a true NF1
phenotype. Skin pigmentation abnormalities have been
reported in patients with r(22) [21,22] and café-au-lait
macules have been associated with multiple ring chromo-
somes (7, 11, 12, 15, 17) [23-27]. In view of the r(22)
abnormality we believe that the enlargement of the right
optic nerve could be due to a meningioma rather than to
an optic glioma.
Conclusion
We conclude that tumours can arise by the combination
of loss of the ring chromosome and a pathogenic NF2
mutation on the remaining chromosome 22 in patients
with r(22). Our findings indicate that patients with a ring
22 should be monitored for NF2-related tumours starting
in adolescence.
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